GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SAB Biotherapeutics Inc (NAS:SABS) » Definitions » Piotroski F-Score

SAB Biotherapeutics (SAB Biotherapeutics) Piotroski F-Score : 2 (As of May. 09, 2024)


View and export this data going back to 2021. Start your Free Trial

What is SAB Biotherapeutics Piotroski F-Score?

Warning Sign:

Piotroski F-Score of 2 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

SAB Biotherapeutics has an F-score of 2. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for SAB Biotherapeutics's Piotroski F-Score or its related term are showing as below:

SABS' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 3   Max: 3
Current: 2

During the past 5 years, the highest Piotroski F-Score of SAB Biotherapeutics was 3. The lowest was 2. And the median was 3.


SAB Biotherapeutics Piotroski F-Score Historical Data

The historical data trend for SAB Biotherapeutics's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SAB Biotherapeutics Piotroski F-Score Chart

SAB Biotherapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
N/A N/A N/A 3.00 2.00

SAB Biotherapeutics Quarterly Data
Dec19 Jun20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.00 N/A 1.00 1.00 2.00

Competitive Comparison of SAB Biotherapeutics's Piotroski F-Score

For the Biotechnology subindustry, SAB Biotherapeutics's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SAB Biotherapeutics's Piotroski F-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SAB Biotherapeutics's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where SAB Biotherapeutics's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Net Income was -7.354 + -6.881 + -5.102 + -22.857 = $-42.19 Mil.
Cash Flow from Operations was -1.606 + -4.899 + -5.168 + -13.447 = $-25.12 Mil.
Revenue was 0.581 + 0 + 0 + 0 = $0.58 Mil.
Gross Profit was 0.581 + 0 + 0 + 0 = $0.58 Mil.
Average Total Assets from the begining of this year (Dec22)
to the end of this year (Dec23) was
(50.905 + 42.672 + 35.443 + 28.336 + 83.941) / 5 = $48.2594 Mil.
Total Assets at the begining of this year (Dec22) was $50.91 Mil.
Long-Term Debt & Capital Lease Obligation was $4.05 Mil.
Total Current Assets was $58.91 Mil.
Total Current Liabilities was $10.81 Mil.
Net Income was 0.986 + -4.776 + -7.076 + -7.875 = $-18.74 Mil.

Revenue was 11.803 + 0 + 0 + 0 = $11.80 Mil.
Gross Profit was 11.803 + 0 + 0 + 0 = $11.80 Mil.
Average Total Assets from the begining of last year (Dec21)
to the end of last year (Dec22) was
(81.141 + 67.472 + 59.155 + 52.507 + 50.905) / 5 = $62.236 Mil.
Total Assets at the begining of last year (Dec21) was $81.14 Mil.
Long-Term Debt & Capital Lease Obligation was $4.53 Mil.
Total Current Assets was $22.10 Mil.
Total Current Liabilities was $14.99 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

SAB Biotherapeutics's current Net Income (TTM) was -42.19. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

SAB Biotherapeutics's current Cash Flow from Operations (TTM) was -25.12. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec22)
=-42.194/50.905
=-0.82887732

ROA (Last Year)=Net Income/Total Assets (Dec21)
=-18.741/81.141
=-0.23096831

SAB Biotherapeutics's return on assets of this year was -0.82887732. SAB Biotherapeutics's return on assets of last year was -0.23096831. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

SAB Biotherapeutics's current Net Income (TTM) was -42.19. SAB Biotherapeutics's current Cash Flow from Operations (TTM) was -25.12. ==> -25.12 > -42.19 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec22 to Dec23
=4.054/48.2594
=0.08400436

Gearing (Last Year: Dec22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec21 to Dec22
=4.533/62.236
=0.07283566

SAB Biotherapeutics's gearing of this year was 0.08400436. SAB Biotherapeutics's gearing of last year was 0.07283566. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec23)=Total Current Assets/Total Current Liabilities
=58.907/10.813
=5.44779432

Current Ratio (Last Year: Dec22)=Total Current Assets/Total Current Liabilities
=22.097/14.993
=1.47382112

SAB Biotherapeutics's current ratio of this year was 5.44779432. SAB Biotherapeutics's current ratio of last year was 1.47382112. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

SAB Biotherapeutics's number of shares in issue this year was 6.761. SAB Biotherapeutics's number of shares in issue last year was 4.497. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=0.581/0.581
=1

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=11.803/11.803
=1

SAB Biotherapeutics's gross margin of this year was 1. SAB Biotherapeutics's gross margin of last year was 1. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec22)
=0.581/50.905
=0.01141342

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec21)
=11.803/81.141
=0.14546284

SAB Biotherapeutics's asset turnover of this year was 0.01141342. SAB Biotherapeutics's asset turnover of last year was 0.14546284. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+0+1+0+1+0+0+0
=2

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

SAB Biotherapeutics has an F-score of 2. It is a bad or low score, which usually implies poor business operation.

SAB Biotherapeutics  (NAS:SABS) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


SAB Biotherapeutics Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of SAB Biotherapeutics's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


SAB Biotherapeutics (SAB Biotherapeutics) Business Description

Traded in Other Exchanges
N/A
Address
2100 East 54th Street North, Sioux Falls, SD, USA, 57104
SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.
Executives
Eddie Joe Sullivan director, 10 percent owner, officer: Chief Executive Officer 2100 E 54TH STREET NORTH, SIOUX FALLS SD 57104
Michael King officer: CHIEF FINANCIAL OFFICER 2100 EAST 54TH STREET NORTH, SIOUX FALLS SD 57104
Samuel J Reich director, officer: Executive Chairman ACUITY PHARMACEUTICALS INC, 3701 MARKET STREET, PHILADELPHIA PA 19104
Sessa Capital Im, L.p. director 888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10019
Andrew Moin director 2100 EAST 54TH STREET NORTH, SIOUX FALLS SD 57104
Sessa Capital (master), L.p. director 888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10019
Sessa Capital Im Gp, Llc director 888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10019
John Petry director 888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10019
Sessa Capital Gp, Llc director 888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10019
Erick Lucera director 138 THISTLE ROAD, NORTH ANDOVER MA 08145
David Charles Link director 2100 E 54TH STREET NORTH, SIOUX FALLS SD 57104
Christine E Hamilton director, 10 percent owner 225 S MAIN AVE, P O BOX 5000, SIOUX FALLS SD 57117
Scott Giberson director 2100 EAST 54TH STREET NORTH, SIOUX FALLS SD 57104
Alexandra Kropotova officer: Chief Medical Officer RIVER OAKS TOWER, 8800 HSC PARKWAY, BYRAN TX 77807
Jeffrey G Spragens director 4400 BISCAYNE BOULEVARD, SUITE 1500, MIAMI FL 33137